Related Experiment Video
Updated: Mar 8, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
New insights into the pathogenesis and treatment of heavy chain deposition disease
Jonathan J Hogan1, Glen S Markowitz2
1Division of Nephrology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Insights
Heavy chain deposition disease involves tissue deposits of truncated monoclonal immunoglobulin heavy chains. Modern therapies like bortezomib significantly improve patient outcomes in this rare condition.
Area of Science:
- Nephrology
- Hematology
- Immunology
Background:
- Heavy chain deposition disease (HCDD) is characterized by tissue deposits of truncated monoclonal immunoglobulin (Ig) heavy chains, typically linked to a plasma cell clone.
- Understanding the clinical, histologic, and molecular features of HCDD is crucial for diagnosis and management.
Purpose of the Study:
- To provide a comprehensive clinical, histologic, and molecular characterization of 15 patients with heavy chain deposition disease.
- To identify key diagnostic markers and assess the impact of treatment on clinical outcomes.
Main Methods:
- Retrospective analysis of clinical data, kidney biopsies, and molecular studies from 15 HCDD patients.
- Histologic examination of tissue deposits and immunofluorescence studies.
- Analysis of serum and urine for monoclonal proteins and complement levels.
Main Results:
- Frequent presence of C3 deposits and hypocomplementemia observed.
- Uniform finding of truncated heavy chains with deletion in the heavy chain constant region 1.
- Abnormal serum-free kappa:lambda ratio was common, even without light-chain deposition.
Conclusions:
- This largest case series to date offers significant insights into HCDD pathogenesis and presentation.
- Modern antiplasma cell therapies, including bortezomib, demonstrate improved clinical outcomes for HCDD patients.
Abstract:
Heavy chain deposition disease is defined by the presence of tissue deposits of truncated monoclonal Ig heavy chains, usually associated with an underlying plasma cell clone. In this issue of Kidney International, Bridoux et al. described the clinical, histologic, and molecular characterization of 15 patients with heavy chain deposition disease, which is the largest case series to date. Notable findings included the frequent presence of C3 deposits and hypocomplementemia, the uniform finding of truncated heavy chains with the deletion in the heavy chain constant region 1, and the common occurrence of an abnormal serum-free κ:λ ratio, despite the absence of light-chain tissue deposition. Importantly, this study showed that clinical outcomes are improved significantly with modern antiplasma cell therapies such as bortezomib.
More Related Videos
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
15:07VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
Published on: December 28, 2015
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Rheumatic Heart Disease I: Introduction
Lysosomal Hydrolases
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Cardiomyopathy II: Dilated Cardiomyopathy